Prescription drug · ANDA
Irinotecan Hydrochloride NDC 63323-193
Irinotecan hydrochloride 20 mg/mL · Injection, Solution · Intravenous · Fresenius Kabi USA, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63323-193-52 | 6332301935263323019352 | 1 VIAL in 1 BOX (63323-193-52) / 2 mL in 1 VIALMarketed from Apr 1, 2009 | |
| 63323-193-55 | 6332301935563323019355 | 1 VIAL in 1 BOX (63323-193-55) / 5 mL in 1 VIALMarketed from Apr 1, 2009 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Irinotecan Hydrochloride
- Generic name (nonproprietary)
- irinotecan hydrochloride
- Active ingredients
- Irinotecan hydrochloride — 20 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Fresenius Kabi USA, LLCNDC labeler code 63323
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 077776
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 63323-193_4e0a18c8-35aa-447c-bd91-b81d7d494d8eSPL ID 4e0a18c8-35aa-447c-bd91-b81d7d494d8eSPL set ID ee45f127-8450-4455-a945-a1f5707f1d39RxCUI 1726319, 1726324UNII 042LAQ1IISUPC 0363323193522, 0363323193553
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N463323019352followed by a unit qualifier and the quantityPackage 63323-0193-52. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 63323-193
- What is NDC 63323-193?
- 63323-193 is the product NDC for Irinotecan Hydrochloride, Irinotecan hydrochloride 20 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Irinotecan Hydrochloride.
- What is the active ingredient?
- Irinotecan hydrochloride.
- Who is the labeler?
- Fresenius Kabi USA, LLC, NDC labeler code 63323. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Irinotecan Hydrochloride?
- 19 other product NDCs are listed under this name. See all Irinotecan Hydrochloride NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Irinotecan Hydrochloride products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Apotex Corp. | 60505-6272 | 60505-6272-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-355 | 55150-0355-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-027 | 16714-0027-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Northstar Rx LLC | 16714-131 | 16714-0131-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-352 | 55150-0352-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-353 | 55150-0353-01 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Eugia US LLC | 55150-354 | 55150-0354-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Gland Pharma Limited | 68083-382 | 68083-0382-01 |
| Irinotecan hydrochloride | Irinotecan hydrochloride 20 mg/mL | InjectionIntravenous | Xiromed LLC | 70700-170 | 70700-0170-22 |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | Apotex Corp. | 60505-6128 | 60505-6128-0060505-6128-01 |